Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 663 • 2019 ACR/ARP Annual Meeting
Peripheral Blood Toll Like Receptor 7 Expression and Serum Interferon Lambda 1 Levels in Systemic Lupus Erythematosus and Their Relation to Disease Activity and Lupus Nephritis
Hayam ElAggan¹, Nahla Farahat ¹, Mohamed Sakr ¹ and Shaymaa Tawfik ¹, ¹Faculty of Medicine, University of Alexandria, Alexandria, Egypt, Alexandria, Egypt
Background/Purpose: Toll-like receptor 7 (TLR7) can sense single-stranded RNA with subsequent induction of different interferon (IFN) types including IFN lambda (IFNL) and may contribute to…
Abstract Number: 894 • 2019 ACR/ARP Annual Meeting
Frequency, Severity and Costs of Flares Increase with Disease Severity in Newly Diagnosed Systematic Lupus Erythematous: A Real-World Cohort Study, United States, 2004–2015
Miao Jiang ¹, Barnabas Desta ¹, Aimee Near ², Xia Wang ¹ and Edward Hammond¹, ¹AstraZeneca, Gaithersburg, MD, ²IQVIA, Durham, NC
Background/Purpose: We evaluated the real-world frequency and severity of flares and associated costs 1 year post diagnosis in a US cohort with newly diagnosed SLE.Methods:…
Abstract Number: 1039 • 2019 ACR/ARP Annual Meeting
Molecular Profiling Identifies Immunologic Subgroups and Informs Mechanism of Action of Baricitinib in SLE
Thomas Dörner¹, Yoshiya Tanaka ², Michelle Petri ³, Josef Smolen ⁴, Daniel Wallace ⁵, Ernst Dow ⁶, Damiano Fantini ⁶, Richard Higgs ⁶, Guilherme Rocha ⁶, Brenda Crowe ⁶, Robert Benschop ⁶, Adam Abel ⁶, Nicole Byers ⁶, Maria Silk ⁶, Stephanie de Bono ⁶ and Robert Hoffman ⁶, ¹Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Medical University of Vienna, Vienna, Austria, ⁵Cedars-Sinai Medical Center/University California at Los Angeles, Los Angeles, CA, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib is an oral selective Janus kinase (JAK) 1 and JAK2 inhibitor. In the Phase II, 24-week, randomized, placebo-controlled, double-blind study JAHH (NCT02708095), once-daily…
Abstract Number: 1558 • 2019 ACR/ARP Annual Meeting
Should Lupus Podocytopathy Be a Subclass in Class I and Class II Lupus Nephritis?
Whitney Bembry¹, Dasha Lopez ², Christopher Mesa ³, Nirupa Patel ³ and Myriam Guevara ⁴, ¹Tulane University School of Medicine, New Orleans, LA, ²Baton Rouge General Hospital, Baton Rouge, LA, ³Louisiana State University School of Medicine, New Orleans, LA, ⁴Louisiana State University School of Medicine, New Orleans
Background/Purpose: Evidence of podocyte effacement on electron microscopy and significant proteinuria in a systemic lupus erythematosus (SLE) patient with biopsy proven minimal mesangial (MM), mesangial…
Abstract Number: 1597 • 2019 ACR/ARP Annual Meeting
Assessing Long-term Poor Outcomes in Systemic Lupus Erythematosus Patients with Acute Coronary Syndromes
Paramjit Singh¹, ¹Kaiser Permanente Fontana, Fontana
Background/Purpose: Systemic lupus erythematosus (SLE) is a significant risk factor for coronary atherosclerosis, independent of the classic risk factors. Previous studies have found poor acute…
Abstract Number: 1735 • 2019 ACR/ARP Annual Meeting
Clinical Variables Influencing Prednisone Dosing Towards the Development of Corticosteroid Treatment Algorithms in Pediatric Proliferative Lupus Nephritis
Nathalie Chalhoub¹, Tingting Qiu ², Jianghong Deng ³, Angela Merritt ², Bin Huang ⁴ and Hermine Brunner ⁴, ¹The University of Cincinnati College of Medicine, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Beijing Children's Hospital, Beijing, China (People's Republic), ⁴Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Corticosteroids (CS) are the mainstay of childhood-onset systemic lupus erythematosus (cSLE) and proliferative lupus nephritis (LN) therapy. However, there are no widely accepted CS…
Abstract Number: 2024 • 2019 ACR/ARP Annual Meeting
Genetics of Longitudinal Kidney Function in Children and Adults with Systemic Lupus Erythematosus
Thai-Son Tang¹, Declan Webber ², Jingjing Cao ³, Daniela Dominguez ⁴, Dafna Gladman ⁵, Andrea Knight ⁶, Deborah Levy ⁷, Lawrence Ng ⁴, Andrew D. Paterson ⁸, Earl D. Silverman ⁹, Zahi Touma ¹⁰, Murray Urowitz ¹⁰, Joan Wither ¹¹, Eleanor M. Pullenayegum ¹² and Linda Hiraki ¹³, ¹Dalla Lana School of Public Health, University of Toronto, Toronto, Canada, ²University of Toronto, The Hospital for Sick Children, Toronto, Canada, ³Genetics & Genome Biology, The Hospital for Sick Children, Toronto, Canada, ⁴Division of Rheumatology, The Hospital for Sick Children, Toronto, Canada, ⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁶Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁸Genetics & Genome Biology, The Hospital for Sick Children, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada, ⁹Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Canada, ¹⁰University Health Network, University of Toronto, Toronto, ON, Canada, ¹¹University Health Network, Krembil Research Institute, Toronto, ON, Canada, ¹²Child Health Evaluative Sciences, The Hospital for Sick Children, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada, ¹³Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Canada
Background/Purpose: Genetics influences kidney function (estimated glomerular filtration rate (eGFR)), systemic lupus erythematosus (SLE) and lupus nephritis (LN) risk. Genome-wide association studies (GWAS) have identified…
Abstract Number: 2284 • 2019 ACR/ARP Annual Meeting
The Titer of Anti-Double Stranded DNA Antibody Could Affect the Apgar Score of Newborns, Which Is Considered as the Predictive Clinical Index for Neurological or Physical Development
Hiromi Shimada¹, Risa Wakiya ², Mai Mahmoud Fahmy Mansour ², Shusaku Nakashima ², Mikiya Kato ², Taichi Miyagi ², Tomohiro Kameda ² and Hiroaki Dobashi ¹, ¹Kagawa University, Kagawa, Japan, ²Kagawa University, Kagawa
Background/Purpose: Recently, the progression of treatment strategy enabled many systemic lupus erythematosus (SLE) women to become mothers. On the other hand, some reports have revealed…
Abstract Number: 2534 • 2019 ACR/ARP Annual Meeting
Vitamin D Reduces Cardiovascular Risk Factors in SLE
Michelle Petri¹, Jessica Li ¹ and Daniel Goldman ², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Vitamin D has effects on the cardiovascular system, including decreased renin-angiotensin, decreased insulin resistance, increased vascular relaxation and decreased vascular smooth muscle cell proliferation,…
Abstract Number: 2734 • 2019 ACR/ARP Annual Meeting
Signaling Lymphocytic Activation Molecule Family (SLAMF) Receptors Deregulation Is Implicated in the Altered Function of NK Cells in Systemic Lupus Erythematosus
Morgane Humbel ¹, Florence Bellanger ¹, Craig Fenwick ², Alice Horisberger ³, Camillo Ribi ³ and Denis Comte¹, ¹Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Epalinges, Vaud, Switzerland, ²Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Epalinhes, Vaud, Switzerland, ³Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Vaud, Switzerland
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease characterized by quantitative and qualitative deficiencies of immune cells. Natural killer (NK) cells are innate…
Abstract Number: 2864 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Intravenous Belimumab in Children with Systemic Lupus Erythematosus: An Across-Trial Comparison with the Adult Belimumab Studies
Antonio Nino¹, Damon L Bass ², Gina Eriksson ¹, Anne Hammer ¹, Beulah Ji ³, Holly Quasny ⁴ and David Roth ⁵, ¹GlaxoSmithKline, Collegeville, ²GlaxoSmithKline, Collegeville, PA, ³GSK, Uxbridge, Middlesex, United Kingdom, ⁴GlaxoSmithKline, Research Triangle Park, ⁵GSK, Collegeville, PA
Background/Purpose: Belimumab (BEL) is the first treatment approved for children with systemic lupus erythematosus (SLE) from 5 years of age and older.1 This approval was…
Abstract Number: 95 • 2019 ACR/ARP Annual Meeting
IL-21-mediated Suppression of STAT5 Phosphorylation Underlies Treg Depletion and Dysfunction in SLE
Hiroshi Kato¹ and Andras Perl ¹, ¹SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: IL-21 activates mechanistic target of rapamycin (mTOR) complexes 1 and 2 which in turn block regulatory T (Treg)-cell differentiation and function in patients with…
Abstract Number: 674 • 2019 ACR/ARP Annual Meeting
Affordability Concerns Prevalent Among Patients with Systemic Lupus Erythematosus (SLE)
Kimberly DeQuattro¹, Laura Trupin ¹, Patricia Katz ¹, Stephanie Rush ¹, Louise Murphy ², Maria Dall'Era ¹ and Jinoos Yazdany ³, ¹University of California, San Francisco, San Francisco, CA, ²Centers for Disease Control and Prevention, Division of Population Health, Atlanta, ³UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: Among rheumatologic conditions, SLE is associated with very high healthcare and out of pocket costs. Little is known about patients’ concerns regarding costs of…
Abstract Number: 896 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Use and Cardiovascular Events Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
April Jorge¹, Na Lu ², Hyon K. Choi ¹, John Esdaile ³, Diane Lacaille ⁴ and J. Antonio Avina-Zubieta ⁵, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hosptial, Boston, MA, ³Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, ⁴Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada, ⁵Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Hydroxychloroquine (HCQ) is near-universally recommended for patients with SLE and is often used in the treatment of RA. Use of HCQ has been associated…
Abstract Number: 1091 • 2019 ACR/ARP Annual Meeting
Risk of Preterm Birth by Timing of Lupus Diagnosis Among Women in the Georgia Lupus Registry
Meghan Angley¹, Penelope P. Howards ¹, Cristina Drenkard ¹ and S Sam Lim ¹, ¹Emory University, Atlanta, GA
Background/Purpose: Women with systemic lupus erythematosus (SLE) are at a greater risk of having a preterm birth than the general population. Most studies examine preterm…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].